Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-08-28Clinical Trial Update: Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) [EARLY_Phase 1]
An early-phase 1 trial is evaluating targeted AML1-ETO neoantigen cytotoxic T cells for relapsed or refractory acute myeloid leukemia with t…
-
CLINICAL_TRIALS research · 2025-08-27Clinical Trial Update: Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia [EARLY_Phase 1]
Early-phase trial evaluating donor-derived CD117 CAR-T cells for relapsed/refractory acute myeloid leukemia; the study is currently recruiti…
-
CLINICAL_TRIALS research · 2025-08-27Clinical Trial Update: Prognostic Impacts of Lipid Profile and BMI in Adult AML
A clinical trial from Assiut University will assess how lipid profile and BMI influence prognosis in adults with acute myeloid leukemia.
-
CLINICAL_TRIALS research · 2025-08-26Clinical Trial Update: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of Tuspetinib (HM43239) in patients…
-
CLINICAL_TRIALS research · 2025-08-26Clinical Trial Update: Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant [Phase 1, Phase 2]
This clinical trial examines maintenance therapy with decitabine and venetoclax after allogeneic stem cell transplant. It is a Phase 1/2 stu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-08-26Clinical Trial Update: Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML [Phase 2]
Phase 2 clinical trial evaluating a metabolically optimized, non-cytotoxic, low-dose weekly decitabine/venetoclax regimen in myelodysplastic…
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Goal Management Training for Adult Survivors of Childhood Leukemia and Non-Hodgkins Lymphoma With Neurocognitive Sequelae [NA]
Clinical trial update for a study evaluating Goal Management Training for adult survivors of childhood acute lymphoblastic leukemia and chil…
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy [Phase 3]
A Phase 3 trial assessing ivosidenib plus azacitidine with or without venetoclax in adults with newly diagnosed IDH1-mutated AML or MDS/AML …
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: A Study of GLB-001 in Patients With Myeloid Malignancies [Phase 1]
A Phase 1 clinical trial evaluating GLB-001 in patients with myeloid malignancies is currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-17Clinical Trial Update: The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT [EARLY_Phase 1]
An early-phase 1 trial evaluating the safety and potential efficacy of donor-derived allogeneic gamma-delta T cells in patients with measura…
-
CLINICAL_TRIALS research · 2025-08-14Clinical Trial Update: Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML [Phase 1]
Phase 1 clinical trial investigating anti-FLT3 CAR-T cells for relapsed/refractory acute myeloid leukemia; currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-14Clinical Trial Update: γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant [EARLY_Phase 1]
This entry describes an early-phase clinical trial of γδ T cell therapy to prevent relapse in high-risk acute myeloid leukemia after transpl…
-
CLINICAL_TRIALS research · 2025-08-14Clinical Trial Update: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia [Phase 1, Phase 2]
This document reports an ongoing Phase 1/2 clinical trial evaluating IMGN632 as a monotherapy or in combination with venetoclax and/or azaci…
-
CLINICAL_TRIALS research · 2025-08-13Clinical Trial Update: Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)
Observational real-world study of adult acute myeloid leukemia patients treated with new drugs; currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-12Clinical Trial Update: Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia [Phase 1]
Phase 1 trial evaluating iadademstat in combination with azacitidine and venetoclax for newly diagnosed acute myeloid leukemia; recruitment …
-
CLINICAL_TRIALS research · 2025-08-12Clinical Trial Update: Venetoclax-Decitabine in Untreated Elderly/Unfit AML [NA]
This clinical trial update indicates recruitment for a venetoclax and decitabine regimen in untreated elderly or unfit adults with acute mye…
-
CLINICAL_TRIALS research · 2025-08-12Clinical Trial Update: Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation [Phase 2]
This clinical trial update describes a Phase 2 study evaluating TCRγδ T cells and memory T cells with selective use of blinatumomab as part …
-
CLINICAL_TRIALS research · 2025-08-11Clinical Trial Update: The Prognostic Significance of Platelet to White Blood Cell Ratio (PWR) in Patients With Acute Myeloid Leukemia
This clinical trial update explores whether the platelet-to-white blood cell ratio has prognostic value in patients with Acute Myeloid Leuke…
-
CLINICAL_TRIALS research · 2025-08-11Clinical Trial Update: Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation [Phase 1]
A Phase 1 dose-escalation study of vorinostat after allogeneic hematopoietic cell transplantation is ongoing.
-
CLINICAL_TRIALS research · 2025-08-11Clinical Trial Update: Muscle Dysfunction in Patients With Haematological Diseases
This clinical trial update describes a study on muscle dysfunction in patients with hematologic diseases, including acute myeloid leukemia, …
-
CLINICAL_TRIALS research · 2025-08-11Clinical Trial Update: Molecular Characterization of Carbapenemase-Producing Enterobacterales [NA]
A clinical trial update describing a planned study at Sohag University on molecular characterization of carbapenemase-producing Enterobacter…
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease [Phase 2]
This update describes a Phase 2 clinical trial aiming to optimize AML treatment based on early peripheral blood minimal residual disease sta…
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia [Phase 3]
A phase 3 clinical trial is evaluating the effectiveness of medium-dose cytarabine combined with venetoclax as consolidation therapy for eld…
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia
This clinical trial update notes that AbbVie is recruiting adults with acute myeloid leukemia in Colombia to assess disease-state changes wh…
-
CLINICAL_TRIALS research · 2025-08-07Clinical Trial Update: Assessment of Geriatric Evaluations Impact on New AML Guidance
A clinical trial sponsored by the Abramson Cancer Center at Penn Medicine is evaluating how geriatric evaluations influence new guidance for…